Repligen

Yahoo Finance • 9 days ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Repligen Corporation WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan... Full story

Yahoo Finance • last month

Repligen Corporation to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthca... Full story

Yahoo Finance • last month

Three Companies Estimated To Be Priced Below Their Intrinsic Value In November 2025

As the Dow Jones Industrial Average reaches new heights amid optimism surrounding a potential end to the U.S. government shutdown, investors are closely watching market fluctuations with mixed performances across major indices. In this env... Full story

Yahoo Finance • 2 months ago

Repligen beats top-line and bottom-line estimates; updates FY25 outlook

* Repligen press release [https://seekingalpha.com/pr/20281673-repligen-reports-third-quarter-2025-financial-results-and-updates-full-year-2025-financial] (NASDAQ:RGEN [https://seekingalpha.com/symbol/RGEN]): Q3 Non-GAAP EPS of $0.46 bea... Full story

Yahoo Finance • 2 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased sequentially and greater than 20% year-over-yearIncreasing revenue guidance to a ra... Full story

Yahoo Finance • 2 months ago

Can Margin Pressures at Repligen (RGEN) Reveal Deeper Shifts in Management’s Investment Strategy?

Recent news reports that Repligen's core business has been underperforming, with declining organic revenue and rising costs leading to a significant drop in adjusted operating margin. This operational underperformance has raised concerns a... Full story

Yahoo Finance • 2 months ago

Repligen to Report Third Quarter 2025 Financial Results

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press relea... Full story

Yahoo Finance • 3 months ago

Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • 3 months ago

These small cap stocks are poised for a comeback – Palisade Capital’s Dan Veru

[Markets Open After S&P Falls Nearly 4% On Monday] Spencer Platt/Getty Images News Dan Veru, chief investment officer and senior partner at Palisade Capital Management, believes small cap stocks (NYSEARCA:IWM [https://seekingalpha.com/sym... Full story

Yahoo Finance • 4 months ago

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.... Full story

Yahoo Finance • 5 months ago

Repligen partners with Novasign to enhance bioprocessing systems

WALTHAM, Mass. - Repligen Corporation (NASDAQ:RGEN), a bioprocessing company with a market capitalization of $6.9 billion and annual revenue of $650 million, has formed a strategic partnership with Austria-based Novasign to integrate machi... Full story

Yahoo Finance • 5 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership... Full story

Yahoo Finance • 5 months ago

Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market

REPLIGEN CORP (NASDAQ:RGEN [https://www.chartmill.com/stock/quote/RGEN]) Q2 2025 EARNINGS: REVENUE BEATS ESTIMATES, EPS MISSES AMID MARKET REACTION Repligen Corp reported its second-quarter 2025 financial results, delivering mixed perform... Full story

Yahoo Finance • 5 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20% year-over-yearIncreasing revenue guidance to range of $715 to $735 million, which represents... Full story

Yahoo Finance • 5 months ago

Repligen Q2 2025 Earnings Preview

* Repligen (NASDAQ:RGEN [https://seekingalpha.com/symbol/RGEN]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. * The consensus EPS Estimate is $0.39 [https://seekingalpha.com/symbol/RGEN/earning... Full story

Yahoo Finance • 5 months ago

Repligen's 39% decline validates InvestingPro's January 2024 bearish call

When InvestingPro’s Fair Value models identified Repligen Corporation (NASDAQ:RGEN) as significantly overvalued in January 2024, the bioprocessing company was trading at $193.40. Today, after an 18-month period that saw the stock decline b... Full story

Yahoo Finance • 5 months ago

Repligen to Report Second Quarter 2025 Financial Results

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release... Full story

Yahoo Finance • 6 months ago

Repligen's SWOT analysis: bioprocessing leader's stock faces growth challenges

Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing company valued at $7 billion, has been making waves in the biopharmaceutical industry with its innovative products and strategic acquisitions. As the company navigates through a p... Full story

Yahoo Finance • 6 months ago

Barclays initiates Repligen stock with overweight rating on bioprocessing strength

Investing.com - Barclays initiated coverage on Repligen (NASDAQ:RGEN) with an overweight rating and a $150.00 price target on Monday. The research firm cited Repligen’s positioning as a bioprocessing pure-play company, noting the sector’s... Full story

Yahoo Finance • 6 months ago

908 Devices appoints co-founder Christopher Brown to board of directors

BOSTON - 908 Devices Inc. (NASDAQ:MASS), a company specializing in handheld devices for chemical analysis, announced Monday the appointment of Christopher D. Brown, PhD, to its Board of Directors, effective immediately. Brown, a co-founde... Full story